Recognition and treatment of idiopathic pulmonary fibrosis

Drugs

Volumn 55, Issue 4, 1998, Pages 555-562

  Nicod, Laurent P ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOSTATIC AGENT; METHYLPREDNISOLONE; NICOTINIC ACID; PIRFENIDONE; PREDNISONE; RELAXIN;

CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; GAS EXCHANGE; GRANULOMATOSIS; HUMAN; KIDNEY FAILURE; LUNG BIOPSY; LUNG FIBROSIS; LUNG LAVAGE; LUNG TRANSPLANTATION; LUNG VOLUME; MAJOR CLINICAL STUDY; META ANALYSIS; REVIEW; SARCOIDOSIS; STEROID THERAPY; THORACOSCOPY; THORACOTOMY; THORAX RADIOGRAPHY; VASCULAR DISEASE;

ADRENAL CORTEX HORMONES; COLCHICINE; CYCLOSPORINE; CYTOKINES; GOUT SUPPRESSANTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; PULMONARY ALVEOLI; PULMONARY FIBROSIS; RANDOMIZED CONTROLLED TRIALS;

EID: 0031966298     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199855040-00006     Document Type: Review

References (35)

1. Webb WR. High resolution lung computed tomography: normal anatomic and pathologic findings. Radiol Clin North Am 1991; 29: 1051-63
2. Crystal RG, Bitterman PB, Rennard SI, et al. Interstitial lung diseases of unknown cause: disorders characterized by chronic inflammation of the lower respiratory tract (second of two parts). N Engl J Med 1984; 310: 235-44
3. Fulmer JD, Roberts WC, Moss ML, et al. Idiopathic pulmonary fibrosis: clinical, histological, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Intern Med 1976; 85: 769-88
4. Orens JB, Kazerooni EA, Martinez FJ, et al. The sensitivity of high-resolution CT in detecting idiopathic pulmonary fibrosis proved by open lung biopsy: prospective study. Chest 1995 July; 108: 109-15
5. Watters LC, King TE, Schwarz MI, et al. A clinical radiographic and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1986; 133: 97-103
6. Wolff, G, Crystal R. Biologic basis of pulmonary fibrosis. In: Crystal R, West J, Weibel E, et al., editors. The lung. New York: Raven Press, 1997: 2509-24
7. Villard J, Dayer-Pastore F, Harnacher J, et al. GRO alpha and interleukin-8 in Pneumocystis carinii or bacterial pneumonia and adult respiratory distress syndrome. Am J Respir Crit Care Med 1995 Nov; 152: 1549-54
8. Rochester CL, Elias JA. Cytokines and cytokine networking in the pathogenesis of interstitial and fibrolic lung disorders. Semin Respir Med 1993; 14: 389-416
9. Behr J, Maier K, Krombach F, et al. Pathogenetic significance of reactive oxygen species in diffuse fibrosing alveolitis. Am Rev Respir Dis 1991; 144: 146-50
10. Cantin AM, Hubbard RC, Crystal RG. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1989; 139: 370-2
11. Fujimoto K, Kubo K, Yamaguchi S, et al. Eosinophil activation in patients with pulmonary fibrosis. Chest 1995; 108: 48-54
12. Sheppard MN, Harrison NK. New perspectives on basic mechanism in lung disease: lung injury, inflammatory mediators, and fibroblast activation in fibrosing alveolitis. Thorax 1992; 47: 1064-74
13. McAnulty RJ, Laurent GJ. Pathogenesis of lung fibrosis and potential new therapeutic strategies. Exp Nephrol 1995; 3: 96-107
14. Kapanci Y, Desmouliere A, Pache JC, et al. Cytoskeletal protein modulation in pulmonary alveolar myofibroblasts during idiopathic pulmonary fibrosis: possible role of transforming growth factor beta and tumor necrosis factor alpha. Am J Respir Crit Care Med 1995 Dec; 152: 2163-9
15. Broekelmann TJ, Limper AH, Colby TV, et al. Transforming growth factor β1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci USA 1991; 88: 6421-46
16. Wilborn J, Crofford LJ, Burdick MD, et al. Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. J Clin Invest 1995 Apr 4: 1861-8
17. Carrington CB, Gaensler EA, Coutu RE, et al. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med 1978; 298: 801-9
18. Turner-Warwick MB, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival. Thorax 1980; 35: 593-9
19. Watters LC, Schwarz MI, Cherniack RM, et al. Idiopathic pulmonary fibrosis: pretreatment bronchoalveolar lavage cellular constituents and their relationships with lung histopathology and clinical response to therapy. Am Rev Respir Dis 1987; 135: 696-704
20. Keogh BA, Bernardo J, Hunninghake GW, et al. Effect of intermittent high dose parenteral corticosteroids on the alveolitis of idiopathic pulmonary fibrosis. Am Rev Respir Dis 1983; 127: 18-22
21. Johnson MA, Wan SK, Snell NJS, et al. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989; 44: 280-8
22. Hanson D, Winterhauer RH, Kirtland SH, et al. Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest 1995 Aug; 108 (2): 305-10
23. Dayton CS, Schwartz DA, Helmers RA, et al. Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy: implications for further studies. Chest 1993; 103: 69-73
24. Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991; 144: 291-6
25. Peters SG, McDougall JC, Douglas WW, et al. Colchicine in the treatment of pulmonary fibrosis. Chest 1993; 103: 101-4
26. De Remee RA. New approaches to the treatment of pulmonary fibrosis [editorial; comment]. Eur Respir J 1994; 7: 461-4
27. Alton EWFW, Johnson M, Turner-Warwick M. Advanced cryptogenic fibrosing alveolitis: preliminary report on treatment with cyclosporin A. Respir Med 1989; 83: 277-9
28. Moolman JA, Bardin PG, Rossouw DJ, et al. Cyclosporin as a treatment for interstitial lung disease of unknown aetiology. Thorax 1991; 46: 592-5
29. Sauty A, Rochat Th, Schoch OD, et al. Case study: pulmonary fibrosis with predominant CD8 lymphocytic alveolitis and anti-Jo-1 antibodies. Eur Respir J. In press
30. Coker RK, Laurent GJ. Anticytokine approaches in pulmonary fibrosis: bringing factors into focus. Thorax 1997; 52: 294-6
31. Giri SN, Hyde DM, Hollinger MA. Effect of antibody to transforming growth factor-beta on bleomycin induced accumulation of lung collagen in mice. Thorax 1993; 48: 959-66
32. Taniyama M, Ohbayashi S, Narita M, et al. Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients. Eur J Clin Pharmacol 1997; 52: 77-8
33. Unemori EN, Pickford LB, Salles AL, et al. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest 1996 Dec; 98 (12): 2739-45
34. Hunninghake GW, Kalica AR. Approaches to the treatment of pulmonary fibrosis [workshop summary]. Am J Respir Crit Care Med 1995; 151: 915-8
35. Behr J, Maier K, Degenkolb B, et al. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Am J Respir Crit Care Med 1997; 156: 1897-901